Bong-Seog Kim

Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non–Small-Cell Lung Cancer Harboring <i>ROS1</i> Rearrangement

Sun Min Lim, Hye Ryun Kim, Jong-Seok Lee et al. · Journal of Clinical Oncology · 2017 · 297 citations · Full text

Inhibitory action of minocycline on lipopolysaccharide-lnduced release of nitric oxide and prostaglandin E2 in BV2 microglial cells

Sung‐Soo Kim, Pil‐Jae Kong, Bong-Seog Kim et al. · Archives of Pharmacal Research · 2004 · 79 citations

Inflammation, Prostaglandin E2, Anti-inflammatory +10

Updated safety and efficacy results from phase I/II study of HM61713 in patients (pts) with EGFR mutation positive non-small cell lung cancer (NSCLC) who failed previous EGFR-tyrosine kinase inhibitor (TKI).

Keunchil Park, Jong-Seok Lee, Ki Hyeong Lee et al. · Journal of Clinical Oncology · 2015 · 50 citations

Surgical Oncology, Phase I/ii Study, T790m Positive Nsclc +18

Pazopanib maintenance after first-line etoposide and platinum chemotherapy in patients with extensive disease small-cell lung cancer: a multicentre, randomised, placebo-controlled Phase II study (KCSG-LU12-07)

Jong‐Mu Sun, Ki Hyeong Lee, Bong-Seog Kim et al. · British Journal of Cancer · 2018 · 42 citations · Full text

BI 1482694 (HM61713), an EGFR mutant-specific inhibitor, in T790M+ NSCLC: Efficacy and safety at the RP2D.

Keunchil Park, Jong-Seok Lee, Ki Hyeong Lee et al. · Journal of Clinical Oncology · 2016 · 41 citations

Oncology, Phase Ii, Malignant Disease +15